Iantrek announces first commercial cases of C.Rex micro-interventional system
C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.
Image credit: AdobeStock/ImageFlow
Medical technology company Iantrek has announced the first commercial cases of its micro-interventional system for canal outflow enhancement designed for glaucoma surgery.1 The cases are part of the company’s pre-launch activities that features the C.Rex technology, used as an ophthalmic surgical system for canal outflow gonio-intervention, according to a news release.
“All conventional approaches have focused on the trabecular meshwork and the inner canal wall,” said Carol Toris, PhD, professor at the University of Nebraska Medical Center, in the release. “We have shown empirically and presented our study at ARVO that dual canal intervention can lead to incremental outflow enhancement over single inner wall goniotomy. Iantrek’s approach is uniquely original as it is able to address outflow resistance in the entire canal.”
C.Rex is a super-elastic nitinol filament technology and remains the only FDA-registered MIGS technology for excisional circumferential trabeculorhexis and dual wall canal intervention. The nitinol filament technology allows for flexible micro-instrumentation with memory-shaped super-elasticity to deliver 360-degrees of excisional, single, or dual wall canalotomy. C.Rex is also the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.1
“There are a lot of trabecular technologies, but this is an interventional breakthrough in non-implantable trabecular outflow surgery,” said Arkadidy Yadgarov, MD, of OMNI Eye Services in Atlanta, GA, and the first surgeon in the country to utilize the advanced technology, in the release. “It is one of the most surgically intuitive MIGS technologies, and the only goniotomy system to enable surgical intervention on the entire canal, not just segmentally. The C.Rex offers circumferential excisional goniotomy which is guided, continuous, comprehensive and can reduce resistant in the outer wall.”
Reference:
Iantrek announces first commercial cases of its C.Rex micro-interventional system for trabecular outflow enhancement. News release. Iantrek. January 13, 2025. Accessed February 3, 2025. https://iantrekmed.com/iantrek-announces-first-commercial-cases-of-its-c-rex-micro-interventional-system-for-trabecular-outflow-enhancement/
